Dark

AKBA
Akebia Therapeutics, Inc.
stock NASDAQ

At Close

May 8, 2025 3:59:57 PM EDT

2.62USD+6.301%(+0.16)10,584,471

2.59Bid 2.62Ask 0.03Spread

Pre-market

May 8, 2025 9:28:30 AM EDT

2.80USD+13.821%(+0.34)775,883

After-hours

May 8, 2025 4:53:30 PM EDT

2.65USD+1.327%(+0.03)4,524

OverviewOptionsHistoricalExchangesShortsMore

open chart

Market Cap

569.45M

CEO

John Butler

Headquarters

Cambridge, Massachusetts, USA

Industry

Biotechnology

AMGN KERX NKTR NVS JNJ XLV

AKBA Stats

Avg. Vol. 10 Day

2,962,791

Avg. Vol. 30 Day

3,815,574

Employees

114

Market Cap

569,452,937

Shares Out.

218,181,202

On/Off Exchange

46%/54%

6 Month Beta

1.16

1 Year Beta

1.25

2 Year Beta

1.21

3 Year Beta

1.41

52 Week Low

0.80

52 Week High

2.89

SMA50

2.04

SMA200

1.78

1 Week

+9.21%

1 Month

+55.36%

3 Month

+21.96%

6 Month

+34.54%

1 Year

+86.43%

2 Year

+146.23%

5 Year

-78.21%

Profile

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia's global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

AKBA Stock Summary

Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock price today is $2.62, and today's volume is 10,584,471. AKBA is up 6.301% today. The 30 day average volume is 3,815,574. AKBA market cap is 569.45M with 218,181,202 shares outstanding.